¥ìªi©ÔÃÄÀò§å TekmiraªÑ»ù‘C45%
¡i©ú³ø±M°T¡j¥[°êÃļtTekmira Pharmaceuticals(¥N¸¹TKMR¢¬TKM)ªÑ»ù¬Q¤É¹O45¢H¡A¦]¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½(FDA)±µªñ§å㥦¥¿¦b¸ÕÅ窺ªvÀø¥ìªi©ÔÃĪ«µ¹¯f¤HªA¥Î¡C
Á`³¡³]¦b¨õ¸Ö¬Ù¥»¨º¤ñ¥«ªºTekmira¡A©P¥|±ßµoÁn©ú»¡¡AFDA¤w¤fÀY¤WÃÒ¹ê¡A§âTKM-EbolaÃĪº¦a¦ì¡A±q¥þ±¼È°±Á{þH¸ÕÅç¡A§ó§ï¬°§½³¡¼È°±Á{þH¸ÕÅç¡A§Y¥i¥H¦³«×¨Ï¥Î¸ÓÃĪ«¡C¸ÓÃĪ«¬OTekmira©M¬ü°êx¤è¦X§@¬ãµo¡A¬O¥þ²y3ºØ¹ï¥ìªi©Ô¯f¬r¥i¯à¦³®ÄÃĪ«¤§¤@¡A¦ý¥¼¦b¤HÅéÃÒ¹êÀø®Ä¡C
Tekmira¬Q¤é¦b¯Ã¬ù¥H¥þ¤é°ª¦¬¥«¡A¦¬³ø20.7¬ü¤¸¡A¤É6.43¬ü¤¸©Î45.06¢H¡F¦b¦h¥««h¦¬³ø22.75¤¸¡A¤É7.14¤¸©Î45.74¢H¡C